Cargando…

Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers

We assessed the efficacy of polaprezinc plus proton pump inhibitor (PPI) treatment for endoscopic submucosal dissection (ESD)-induced ulcer healing compared with rebamipide plus PPI treatment. BACKGROUND: ESD has been widely used as a local treatment option that cures gastric neoplasms. However, it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Da Hyun, Park, Jun Chul, Lee, Yong Chan, Lee, Sang Kil, Shin, Sung Kwan, Chung, Hyunsoo, Park, Jae Jun, Kim, Jie-Hyun, Youn, Young Hoon, Park, Hyojin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	ALIMENTARY TRACT: Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960146/ https://www.ncbi.nlm.nih.gov/pubmed/32341237 http://dx.doi.org/10.1097/MCG.0000000000001357

Ejemplares similares

Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy
por: Holmberg, Dag, et al.
Publicado: (2022)

Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study
por: Maret-Ouda, John, et al.
Publicado: (2023)

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease
por: Miwa, Hiroto, et al.
Publicado: (2019)

Rebamipide Plus Proton Pump Inhibitor Versus Proton Pump Inhibitor Alone in the Treatment of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Retracted: A Meta-Analysis of Randomized Controlled Trials
por: Xiong, Ji, et al.
Publicado: (2014)

Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2017)

Notice of Retraction: Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials
Publicado: (2014)

Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease
por: Gweon, Tae-Geun, et al.
Publicado: (2018)

A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Jung, Da Hyun, et al.
Publicado: (2021)

Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy
por: Nakamura, Kazuhiko, et al.
Publicado: (2016)

Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis
por: Nishizawa, Toshihiro, et al.
Publicado: (2015)

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics
por: Revaiah, Pruthvi C, et al.
Publicado: (2018)

Selective expansion of intraepithelial lymphocytes expressing the HLA-E–specific natural killer receptor CD94 in celiac disease()()
por: Jabri*, ‡, §, Bana, et al.
Publicado: (2000)

Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases
por: Zhang, Hu, et al.
Publicado: (2020)

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine
por: Siniscalchi, Monica, et al.
Publicado: (2020)

Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey
por: Marasco, Giovanni, et al.
Publicado: (2020)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
por: Bossa, Fabrizio, et al.
Publicado: (2021)

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
por: Maconi, Giovanni, et al.
Publicado: (2021)

Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study
por: Ianiro, Gianluca, et al.
Publicado: (2020)

Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area
por: Elli, Luca, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
por: Arrigo, Serena, et al.
Publicado: (2021)

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023)

The natural history of COVID-19 in vaccinated inflammatory bowel disease patients
por: Viazis, N., et al.
Publicado: (2023)

Endoscopic Submucosal Dissection in the Era of Proton Pump Inhibitors
por: Isomoto, Hajime, et al.
Publicado: (2009)

Clinicopathologic Analysis of Proton Pump Inhibitor-Responsive Esophageal Eosinophilia in Korean Patients
por: Jung, Da Hyun, et al.
Publicado: (2016)

Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis
por: Liu, Junyuan, et al.
Publicado: (2020)

Effectiveness of proton pump inhibitor in unexplained chronic cough
por: Park, Hye Jung, et al.
Publicado: (2017)

Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Tariq, Muhammad Ali, et al.
Publicado: (2022)

Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden
por: Brusselaers, Nele, et al.
Publicado: (2019)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
por: Lim, Hyun Chul, et al.
Publicado: (2013)

Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
por: Lee, Hyun-Jung, et al.
Publicado: (2021)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Proton pump inhibitor-induced fundic gland polyposis
por: Park, Young Joo, et al.
Publicado: (2017)

Rebamipide as a Potential Alternative Gastroprotective Agent to Proton Pump Inhibitor in Elderly Chronic Nonsteroidal Anti-Inflammatory Drug Users without Risk Factors
por: Lee, Mee Yeon, et al.
Publicado: (2022)

The possible roles of hyperpolarization-activated cyclic nucleotide channels in regulating pacemaker activity in colonic interstitial cells of Cajal
por: Shahi, Pawan Kumar, et al.
Publicado: (2013)

Combination of proton pump inhibitor and rebamipide, a free radical scavenger, promotes artificial ulcer healing after endoscopic submucosal dissection with dissection size >40 mm
por: Araki, Hiroshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fgm8qn9b3uhiudrm0akrlkt3ku